

The takeover sparks a gene-editing rally—Following its existing collaboration on cardiovascular gene therapies, the acquisition is driving Verve shares up ~75–80% and boosting optimism across the gene‑editing sector.
Cat-GPT—Let’s be honest: Cats already run our lives, so this may as well be the root source of Sky-Net. What would the “Cat-Matrix” look like? “The meow machine you never knew you needed,” Business Insider.
We really need a proper diagnostic definition and identification process—The variability in long COVID symptoms and reporting across demographic groups presents significant challenges for diagnosis and research.
Opportunities for Implementation—Since the Orphan Drug Act was passed in 1983, there have been tremendous advances in research, innovation and regulatory policies that have spurred development of new treatments for rare diseases, but less than 5% of rare diseases have approved treatments on the market.
The Lancet reported the study of first global analysis of antimicrobial resistance trends.—“Antimicrobial medicines are one of the cornerstones of modern healthcare, and increasing resistance to them is a major cause for concern,” says study author Dr. Mohsen Naghavi.
Are You Prepared for Evolving FDA Oversight?—The FDA is soliciting comments and feedback regarding the importance of AI safety and effectiveness considerations in advance of its upcoming Digital Health Advisory Committee Meeting.
When researchers know what to look for we can start explaining a lot of “unidentified” diseases.—Several new tick-borne viruses have been discovered in various parts of the world in the past 10 years. The latest may be a previously unknown orthonairovirus known as Wetland virus (WELV).
Centers for Medicare & Medicaid Services report targets these shortfalls—The pandemic brought attention to many parts of our healthcare system including long term care. An aging population is sure to place continuing stress on a care model that is already stretched.